Navigation Links
Alexza Announces Preliminary Results from its AZ-104 (Staccato(R) Loxapine) Phase 2b Trial in Patients with Migraine Headache
Date:9/14/2009

ive findings. However, there is much value we can bring to patients through our Staccato technology, as evidenced by our late-stage, pre-NDA program with AZ-004 (Staccato loxapine, high dose) for the acute treatment of agitation."

AZ-104 Phase 2b Clinical Trial Design

The AZ-104 Phase 2b clinical trial was an outpatient, multi-center, randomized, double-blind, single administration, placebo-controlled study. The study was designed to evaluate the treatment of a single migraine attack of moderate to severe intensity in each of approximately 360 migraine patients, with or without aura. Two doses of AZ-104 (1.25 mg and 2.5 mg) and placebo were evaluated in the clinical trial. The study enrolled a total of 366 patients: 125 patients in the placebo dose group, 121 patients in the 1.25 mg dose group, and 120 patients in the 2.5 mg dose group.

Patients rated their headache pain using the International Headache Society (IHS) 4-point rating scale. The primary efficacy endpoint was headache pain relief (headache pain rated as mild or none) at 2 hours post-dose. Secondary efficacy endpoints for the clinical trial included various additional measurements of pain relief, as well as effects on nausea, vomiting, phonophobia and photophobia. All results were considered statistically significant at the p < 0.05 level, as compared to placebo, and all analyses were made on an intent-to-treat basis. Safety evaluations were also made throughout the clinical trial period.

Primary Efficacy Endpoint

AZ-104 was numerically superior to placebo in pain-relief at 2-hours post-dose, but these differences were not statistically significant. Pain relief was observed in 56% of patients receiving the 2.5 mg dose (p=0.11) and 54% of patients receiving the 1.25 mg dose (p=0.12), as compared to 45% of patients receiving placebo.

Another commonly used measure of efficacy i
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 /PRNewswire/ ... the prostate cancer treatment continuum was highlighted prominently ... the American Urological Association (AUA), in San Diego.  ... invasive high intensity focused ultrasound (HIFU) technology, the ... localize disease, and for urologists to consider minimally ...
(Date:5/23/2013)... -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative ... that it has initiated dosing in a Phase I ... therapy for the treatment of HCV infection. This study will ... to assess both the safety and antiviral efficacy of ... the treatment of chronic HCV infections and is based ...
(Date:5/23/2013)... AVIV, Israel , May 23, 2013 ... BrainTech Israel 2013 , Israel,s ... place on October 14 th -15 th in ... nd most innovative city in the world by the ... "Start-up Nation." BrainTech Israel 2013 will showcase the ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... in Excess of $10 Million; Access Gains Second ... SEOUL, South Korea, Feb. 19 ... and JCOM Ltd , an ... the Republic of Korea, today announced the signing of ...
... Were Performed on AMI Patients in 2008, According to ... Millennium Research Group,s (MRG,s) US Markets for Interventional ... stents will continue to climb steadily through 2013, driven ... coronary intervention (PCI) in Acute Myocardial Infarction (AMI) patients, ...
Cached Medicine Technology:Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 2Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 3Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 4Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use 2
(Date:5/23/2013)... Approximately a year ago, the leading journal Science ... Alzheimer,s drug. A significant breakthrough and an important starting ... Bart De Strooper Alzheimer,s researcher at VIB and ... Rudi D,Hooge KU Leuven and scientists at ... various Alzheimer,s animal test models. Their results were different, ...
(Date:5/23/2013)... to be tested in a clinical trial by a ... Alzheimer,s disease has failed to work with the same ... to results of a study by University of Florida ... affiliated with the Evelyn F. and William L. McKnight ... importance of verifying promising research results before investing in ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
(Date:5/23/2013)... Fort Myers, FL (PRWEB) May 23, 2013 ... daring prediction in the midst of growing numbers of H7N9 ... of UV-Aid, Predict H7N9 Bird Flu Cases Will Subside in ... of May 13th no new cases have been reported. ... of the flu is as predictable as flowers budding in ...
(Date:5/23/2013)... 23 (HealthDay News) -- Schools should ensure that ... activity each day to support their health and ... report. Although previous studies show 60 ... health and development, it,s estimated that only about ... this recommendation, according to the report from the ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2
... more clinical preventive services, dedicate funding source to public ... 11 Partnership for Prevention today unveiled health ... and health promotion efforts to tackle the chronic diseases ... , Under these proposals, federally ...
... Inc. (Nasdaq: PTIE ) has received a Complete Response ... New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of ... the NDA is not approved in its present form. ... non-clinical data will be required to support the approval of REMOXY. ...
... touted as the "cure" for health care, but a new ... that implementation of technology and related devices is not a ... safety of patient care. , , ... to understanding when a technology may (or may not) be ...
... Dental Management,Services, Inc. (Nasdaq: BDMS ), operators ... The Company,s board of directors,has declared a quarterly ... stock.,The dividend is payable January 9, 2009, to shareholders ... Birner Dental Management Services, Inc. acquires, develops, ...
... agonists may cause asthma problems and death, agency officials ... of four asthma medications will be weighed by a U.S. ... hearings end Thursday. , The controversy over these drugs has ... recently calling for banning the use of these drugs for ...
... PRA International, a leading,Clinical Research Organization, announces ... Mexico. With years of long-standing South American ... The region,s existing base of clinical,sites with expertise ... to PRA,s therapeutic focus. The expansion is ...
Cached Medicine News:Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 3Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 2Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 3Health News:FDA Panel Mulls Safety of Asthma Meds 2Health News:FDA Panel Mulls Safety of Asthma Meds 3Health News:PRA International Expands Operations in Mexico 2
... provides a simple, fast and cost-effective method ... samples. This system utilizes guanidine thiocyanate and ... and denature proteins. Purified viral RNA is ... and RNase protection assays. This system is ...
... The Titertek MAP-C2 is designed for ... the instrument is the S60 Stacker that ... removable magazines. The MAP-C2 base model is ... assembly. Auxiliary Digiflex pipetting units may be ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
The IL 682 is the Gold Standard for CO-Oximetry analysis....
Medicine Products: